Aptevo Therapeutics Inc (APVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -11,508 | -5,175 | 2,773 | 8,027 | 12,669 |
| Depreciation Amortization | 451 | 328 | 178 | 901 | 740 |
| Accounts payable and accrued liabilities | 129 | 205 | -909 | -394 | -1,383 |
| Other Working Capital | 2,735 | 3,220 | 690 | 2,144 | 3,983 |
| Other Operating Activity | 1,716 | 1,185 | 1,834 | -31,700 | -31,092 |
| Operating Cash Flow | $-6,477 | $-237 | $4,566 | $-21,022 | $-15,083 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -29 | -29 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $-29 | $-29 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -3,467 | -3,467 | -3,467 | -12,267 | -11,767 |
| Common Stock Issued | 6,427 | 2,083 | 1,602 | 6,934 | 436 |
| Other Financing Activity | -8 | -8 | -8 | 2,717 | 2,717 |
| Financing Cash Flow | $2,952 | $-1,392 | $-1,873 | $-2,616 | $-8,614 |
| Beginning Cash Position | 22,635 | 22,635 | 22,635 | 46,303 | 46,303 |
| End Cash Position | 19,110 | 21,006 | 25,328 | 22,636 | 22,577 |
| Net Cash Flow | $-3,525 | $-1,629 | $2,693 | $-23,667 | $-23,726 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,477 | -237 | 4,566 | -21,022 | -15,083 |
| Capital Expenditure | N/A | N/A | N/A | -29 | -29 |
| Free Cash Flow | -6,477 | -237 | 4,566 | -21,051 | -15,112 |